Your browser doesn't support javascript.
loading
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study.
Wang, Ruixi; Liu, Shiliang; Chen, Baoqing; Li, Qiaoqiao; Cheng, Xingyuan; Zhu, Yujia; Zhang, Li; Hu, Yonghong; Liu, Mengzhong; Hu, Yingying; Xi, Mian.
Afiliación
  • Wang R; State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China.
  • Liu S; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Chen B; State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China.
  • Li Q; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Cheng X; State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China.
  • Zhu Y; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Zhang L; State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China.
  • Hu Y; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Liu M; State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China.
  • Hu Y; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Xi M; State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China.
Br J Cancer ; 131(4): 709-717, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38937623
ABSTRACT

BACKGROUND:

A phase II trial (EC-CRT-001) demonstrated the promising efficacy of combining toripalimab (an anti-PD-1 antibody) with definitive chemoradiotherapy (CRT) for locally advanced oesophageal squamous cell carcinoma (ESCC). Biomarkers are key to identifying patients who may benefit from this therapeutic approach.

METHODS:

Of the 42 patients with ESCC who received toripalimab combined with definitive CRT, 37 were included in this analysis. Baseline assessments included PET/CT metabolic parameters (SUVmax, SUVmean, SUVpeak, MTV, and TLG), RNA sequencing of tumour biopsies to quantify the tissue mutational burden (TMB), and multiplex immunofluorescence staining to estimate immune cell infiltration in the tumour microenvironment (TME). Frozen neoplastic samples were procured for RNA sequencing to further explore the immune-related TME.

RESULTS:

Among the 37 patients, high baseline SUVmax (≥12.0; OR = 6.5, 95% CI 1.4-48.2, p = 0.032) and TLG (≥121.8; OR = 6.8, 95% CI 1.6-33.5, p = 0.012) were significantly correlated with lower complete response rates. All five PET/CT parameters were notably associated with overall survival; only SUVmax and TLG were associated with a significantly worse progression-free survival. A trend towards an inverse correlation was observed between SUVmax and TMB (R = -0.33, p = 0.062). PD-1 + CD8 + T cell infiltration was negatively correlated with MTV (R = -0.355, p = 0.034) and TLG (R = -0.385, p = 0.021). Moreover, RNA sequencing revealed that the high TLG subgroup exhibited low immune cell infiltration, indicating an immunosuppressive landscape.

CONCLUSIONS:

High baseline SUVmax and TLG might predict poorer treatment response and worse survival in patients with ESCC undergoing immunotherapy combined with CRT. In addition, high PET/CT metabolic parameters, particularly TLG, were correlated with an immunosuppressive TME, which warrants further exploration.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Microambiente Tumoral / Quimioradioterapia / Tomografía Computarizada por Tomografía de Emisión de Positrones / Carcinoma de Células Escamosas de Esófago / Inmunoterapia Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Microambiente Tumoral / Quimioradioterapia / Tomografía Computarizada por Tomografía de Emisión de Positrones / Carcinoma de Células Escamosas de Esófago / Inmunoterapia Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2024 Tipo del documento: Article País de afiliación: China